Steven A Rosenberg, M.D.
National Cancer Institute (NCI) · National Cancer Institute, National Institutes of Health · NCI, NIH
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Registry trials as an overall official
40
all conditions, ClinicalTrials.gov
NIH grants tied to them
0
NIH RePORTER
Trial papers in breast cancer
0
PubMed author-name match
Trials
Studies that name Steven A Rosenberg, M.D. as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:38 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06253520 · Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerNational Cancer Institute (NCI) · active not recruiting · Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer · principal investigator
- N/ANCT05600933 · Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentNational Cancer Institute (NCI) · enrolling by invitation · Solid Tumors, Hematologic Malignancy, Gastrointestinal Cancer · principal investigator
- Ph2NCT04536922 · Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of PembrolizumabNational Cancer Institute (NCI) · withdrawn · Metastatic HPV-16 Positive Squamous Cell Anal Cancer · principal investigator
- Ph2NCT04102436 · Non-Viral TCR Gene TherapyNational Cancer Institute (NCI) · withdrawn · Endocrine/Neuroendocrine, Non-Small Cell Lung Cancer, Breast Cancer · principal investigator
- Ph1/Ph2NCT03480152 · Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerNational Cancer Institute (NCI) · terminated · Melanoma, Colon Cancer, Gastrointestinal Cancer · principal investigator
- Ph2NCT03412877 · Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic CancerNational Cancer Institute (NCI) · recruiting · Endocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer · principal investigator
- N/ANCT03407040 · Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapyNational Cancer Institute (NCI) · terminated · Gastrointestinal Cancers, Breast Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT03300843 · Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerNational Cancer Institute (NCI) · terminated · Melanoma, Gastrointestinal Cancer, Breast Cancer · principal investigator
- Ph1NCT02489266 · In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic MelanomaNational Cancer Institute (NCI) · withdrawn · Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT02153905 · T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 PositiveNational Cancer Institute (NCI) · terminated · Breast Cancer, Cervical Cancer, Renal Cancer · principal investigator
- Ph2NCT02111863 · Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Melanoma, Skin Cancer · principal investigator
- Ph1/Ph2NCT02111850 · T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-DP0401 PositiveNational Cancer Institute (NCI) · completed · Cervical Cancer, Renal Cancer, Urothelial Cancer · principal investigator
- Ph2NCT02062359 · T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Melanoma · principal investigator
- Ph2NCT01967823 · T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing CancerNational Cancer Institute (NCI) · completed · Melanoma, Meningioma, Breast Cancer · principal investigator
- N/ANCT01658917 · Collecting Solid Tumor Tissue to Identify New TreatmentsNational Cancer Institute (NCI) · completed · Gastrointestinal Cancer, Liver Cancer, Pancreatic Cancer · principal investigator
- Ph2NCT01585428 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated CancersNational Cancer Institute (NCI) · completed · Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer · principal investigator
- Ph1NCT01585415 · Vemurafenib and White Blood Cell Therapy for Advanced MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Melanoma · principal investigator
- Ph1/Ph2NCT01583686 · CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic CancerNational Cancer Institute (NCI) · terminated · Cervical Cancer, Pancreatic Cancer, Ovarian Cancer · principal investigator
- Ph2NCT01468818 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1NCT01457131 · Modified White Blood Cells That Secrete IL-2 and Express a Protein That Targets the ESO-1tumor Protein for Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Melanoma, Metastatic Renal Cancer · principal investigator
- Ph1/Ph2NCT01454596 · CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIIINational Cancer Institute (NCI) · completed · Malignant Glioma, Glioblastoma, Brain Cancer · principal investigator
- Ph2NCT01369875 · Modified Tumor Infiltrating Lymphocytes for Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1/Ph2NCT01369888 · Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph2NCT01319565 · Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...National Cancer Institute (NCI) · completed · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph1/Ph2NCT01273181 · MAGE-A3/12 Metastatic Cancer Treatment With Anti-MAGE-A3/12 TCR-Gene Engineered LymphocytesNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Renal Cancer, Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT01236573 · Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating LymphocytesNational Institutes of Health Clinical Center (CC) · terminated · Skin Cancer, Metastatic Melanoma · principal investigator
- Ph1/Ph2NCT01218867 · CAR T Cell Receptor Immunotherapy Targeting VEGFR2 for Patients With Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Cancer, Metastatic Melanoma, Renal Cancer · principal investigator
- Ph2NCT01174121 · Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic CancerNational Cancer Institute (NCI) · recruiting · Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Ovarian Cancer · principal investigator
- Ph1/Ph2NCT00924326 · CAR T Cell Receptor Immunotherapy for Patients With B-cell LymphomaNational Cancer Institute (NCI) · completed · Primary Mediastinal B-cell Lymphoma, Diffuse, Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma · principal investigator
- Ph1/Ph2NCT00924287 · Gene Therapy Using Anti-Her-2 Cells to Treat Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Cancer · principal investigator
- N/ANCT00923026 · Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch StudiesNational Cancer Institute (NCI) · enrolling by invitation · Melanoma, Adenocarcinoma, Carcinoma NOS · principal investigator
- Ph2NCT00670748 · Chemotherapy Followed by ESO-1 Lymphocytes and Aldesleukin to Treat Metastatic CancerNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Metastatic Renal Cell Cancer, Metastatic Cancer · principal investigator
- Ph2NCT00612222 · Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph2NCT00610311 · Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced MelanomaNational Cancer Institute (NCI) · terminated · Metastatic Melanoma, Skin Cancer · principal investigator
- Ph2NCT00393029 · Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered LymphocytesNational Cancer Institute (NCI) · completed · Anti-p53 TCR-Gene · principal investigator
- Ph2NCT00314106 · Chemotherapy, Irradiation, Cell Infusions, and Interleukin-2 to Treat Metastatic MelanomaNational Cancer Institute (NCI) · completed · Metastatic Melanoma · principal investigator
- Ph2NCT00273910 · Evaluation of the Impact of Adjuvants Accompanying Peptide Immunization in High-Risk MelanomaNational Cancer Institute (NCI) · completed · High-Risk Melanoma · principal investigator
- N/ANCT00068003 · Harvesting Cells for Experimental Cancer TreatmentsNational Cancer Institute (NCI) · enrolling by invitation · Melanoma, Gastrointestinal Cancer, Metastatic Cancer · principal investigator
- Ph2NCT00059475 · Peptide Vaccination for Patients at High Risk for Recurrent MelanomaNational Cancer Institute (NCI) · completed · Melanoma · principal investigator
- N/ANCT00001823 · Evaluation for NCI Surgery Branch Clinical Research ProtocolsNational Cancer Institute (NCI) · recruiting · Synovial Cell Cancer, Melanoma, Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:38 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in breast cancer.